Matt Hoffman

Treatment with eptinezumab resulted in an average reduction of 8.2 monthly migraine days.

Challenges perist in the use of opioids, anti-inflammatories, and agents to treat pain in the elderly.

Fingolimod was previously approved to treat relapsing multiple sclerosis as a once-daily disease-modifying therapy.

RT-100 AC6 treats patients with heart failure with reduced ejection fraction.

By 2060, 15 million people in the United States will be living with mild cognitive impairment due to Alzheimer’s disease.

Synthetic cannabis-like therapy dronabinol associated with a lower overall apnea/hypopnea index compared with placebo.

A cancer diagnosis in young patients can cause post-traumatic stress disorder that can persist long afterwards.

Patients who engage in lifestyle changes can effectively prevent or at least delay a lifelong, chronic disease.

Heplisav-B is the only 2-dose hepatitis B vaccine recombinant approved in the United States.

Vedolizumab (Entyvio) remains consistent in its safety profile in study of real-world data on ulcerative colitis and Crohn's disease.

Two supplemental biologics license applications granted to golimumab to treat adults with psoriatic arthritis and adults with active ankylosing spondylitis.

Golimumab is the only fully-human anti-tumor necrosis factor (TNF) alpha therapy that is administered with a 30-minute infusion.

Trial to analyze which commonly prescribed therapies can reduce exacerbations in patients with chronic obstructive pulmonary disease.

Once-weekly injection of semaglutide recommended for approval for improved glycemic control in adults with type 2 diabetes.

Merck has entered an agreement to develop KalVista Pharmaceuticals’ investigational DME drug.

Zilretta is the first non-opioid, extended-release, intra-articular injection for the treatment of osteoarthritis knee pain.

Gabapentin and opioids are often prescribed together to treat chronic pain and both have shown a potentially fatal risk of breathing suppression.

It is currently the first and only extended-release, intra-articular injection available for OA.

Spending for adalimumab has tripled from 2012 from $4.5 billion.

Guanfacine (Intuniv) for attention-deficit hyperactivity disorder (ADHD) shows marked clinical improvement in global functioning.

FDA advisory committee votes the data was inconclusive on ataluren (translarna), a first-in-class oral treatment for Duchenne muscular dystrophy.

Hundreds of websites selling unapproved drugs, including opioids, antibiotics, and injectable epinephrine products.

Psychedelic-assisted MDMA psychotherapy will be evaluated in Phase 3 trials for PTSD.

An estimated 2.7 million Americans have hepatitis C, too many for specialists to be the sole provider of anti-HCV therapy.

Repatha combined with statin therapy may reduce cardiovascular events.

Severe diabetic retinopathy has a more detrimental effect on visual function than lesser forms of the disease.